Open Label Interventional Multicenter Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Successfully Completed the Phase 2 or Phase 3 Studies
Phase of Trial: Phase III
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Eliglustat (Primary)
- Indications Gaucher's disease
- Focus Registrational; Therapeutic Use
- Acronyms EXOSKEL
- Sponsors Sanofi Genzyme
- 29 Jan 2018 Planned number of patients changed from 40 to 32.
- 13 Jul 2017 Planned End Date changed from 31 May 2021 to 22 Jun 2021.
- 13 Jul 2017 Planned primary completion date changed from 31 May 2021 to 22 Jun 2021.